Furthermore, comprehensive flow cytometry analysis of tumor-infiltrating lymphocytes (TILs) harvested at the experimental endpoint (Day 42) revealed that HER2-CXCR5-CCR6-CAR T treatment significantly enhanced both the frequency and total number of infiltrating CAR T cells within tumor tissues compared to HER2-CXCR5-CAR T and HER2-CCR6-CAR T treatments (Fig. 6B and Fig. S8A-C). This evidence concerns the gene CCR6 and neoplasm.